Latest News

Managing Director of Merck Healthcare Australia and RAP Strategic Champion Josie Downey said the scholarship program would help nurture the next generation of Indigenous STEM leaders, “fostering diversity, inclusion and belonging within the industry.”

Orthocell (ASX:OCC) has secured $30 million through an institutional placement to accelerate the global commercialisation of its flagship nerve repair product and expand its regenerative medicine portfolio.

Amplia Therapeutics (ASX:ATX) is moving to significantly expand its footprint in the United States, launching a capital markets campaign alongside the ongoing development of its promising FAK inhibitor for pancreatic cancer.

Astellas Pharma and Pfizer have announced unprecedented results from the pivotal Phase 3 EV-303 clinical trial (KEYNOTE-905), with the combination of PADCEV (enfortumab vedotin) and MSD's KEYTRUDA (pembrolizumab) delivering significant survival benefits for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Australian biotechnology company AdvanCell has unveiled the first clinical results of its novel targeted alpha therapy 212Pb-ADVC001 for prostate cancer at the European Society for Medical Oncology Congress 2025, marking a significant moment in the evolution of PSMA-targeted radioligand therapy.

US President Donald Trump has announced his administration's third 'Most Favored Nation' pharmaceutical pricing agreement, this one with a focus on fertility treatments.

The decision to streamline the new listings of two BMS immunotherapies represents a rare moment of common sense. By trusting clinicians and using risk-sharing to manage costs, the move replaces years of bureaucratic complexity with a rational pathway. Yet its lasting impact depends on whether stakeholders work to turn a bold exception into a new standard.

“The recommendation talks about this being a novel approach that might point the way to similar approaches in future,” said Owen Smith, General Manager of BMS Australia and New Zealand.

Bristol Myers Squibb has achieved a world-first milestone, becoming the first employer accredited as Menopause Friendly in two geographical regions, the UK and Australia.

David Ricks, Lilly’s Global CEO, previously highlighted the 600-day delay in the reimbursement of the breast cancer therapy as emblematic of access challenges in Australia.

We discuss what could be a significant policy shift in PBS decision-making, with clinical judgement backed by what is a 'common sense' outcome. It could be a new precedent, but only if all stakeholders demand clarity on the criteria so that it can be applied more broadly. We also reflect on patient advocacy in New Zealand, where access has become a political issue and the focus of a significant discussion at this week's Valuing Life Summit in Wellington.

Viral Vector Manufacturing Facility and Chimeric Therapeutics have signed a Letter of Intent to establish a supplier partnership focused on the development and GMP-grade manufacturing of lentiviral vectors for use in clinical-stage CAR-T therapy programs.